Fox News offers a new way to absorb their articles audibly. Recent findings show a promising treatment for endometrial cancer. In a Phase 3 clinical trial, Merck’s investigational drug, sacituzumab tirumotecan (sac-TMT), achieved key goals of improving overall and progression-free survival for patients with advanced or recurrent endometrial cancer.
The TroFuse-005 trial is noted as the first global Phase 3 study to show a significant survival improvement compared to chemotherapy, according to Merck. This is also the inaugural antibody-drug conjugate (ADC) achieving such results in this patient group. ADCs deliver targeted cancer therapy, efficiently attacking tumor cells while sparing healthy tissue. Sac-TMT is administered bi-weekly through IV infusion.
Involving 776 patients whose condition previously worsened post platinum chemotherapy and immunotherapy, this trial randomly assigned patients to receive sac-TMT or the physician’s choice of doxorubicin or paclitaxel. Participants knew which treatment they received. Results showed significant clinical improvement for those on sac-TMT.
Merck reported meeting response rate benchmarks with side effects aligning with previous studies. However, they withheld specific survival benefit data, response rate, or side effect details, with plans to present findings at a medical meeting. Dr. Domenica Lorusso, the global lead investigator, suggests sac-TMT may address an urgent need for advanced endometrial cancer patients. This cancer is one of the few increasing in both incidence and mortality.
Dr. Brian Slomovitz, co-director of gynecologic oncology at Mount Sinai, emphasized that endometrial cancer deaths now exceed those from ovarian cancer, marking it the deadliest gynecologic malignancy in the U.S. He highlighted that while immunotherapy has advanced care standards, better treatment options for recurrent cases remain critical.
Dr. Slomovitz added that if complete data corroborates these findings, key questions will be regarding the survival benefit magnitude and toxicity profile, determining sac-TMT’s role. He emphasized that improving overall survival in recurrent disease offers substantial value for patients and families.
Angelica Stabile, a lifestyle reporter for Fox News Digital, covered this development.